Quidel Corp
F:QL1

Watchlist Manager
Quidel Corp Logo
Quidel Corp
F:QL1
Watchlist
Price: 81.28 EUR 0.82%
Market Cap: €5.4B

EV/EBIT

58
Current
49%
More Expensive
vs 3-y average of 38.8

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
58
=
Enterprise Value
€3.8B
/
EBIT
$54.8m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
58
=
Enterprise Value
€3.8B
/
EBIT
$54.8m

Valuation Scenarios

Quidel Corp is trading above its 3-year average

If EV/EBIT returns to its 3-Year Average (38.8), the stock would be worth €54.41 (33% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-67%
Maximum Upside
No Upside Scenarios
Average Downside
57%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 58 €81.28
0%
3-Year Average 38.8 €54.41
-33%
5-Year Average 20.9 €29.35
-64%
Industry Average 19.2 €26.97
-67%
Country Average 19.6 €27.49
-66%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
€3.8B
/
Dec 2025
$54.8m
=
58
Current
€3.8B
/
Dec 2025
$390.2m
=
9.8
Forward
€3.8B
/
Dec 2026
$404.3m
=
9.5
Forward
€3.8B
/
Dec 2027
$471.3m
=
8.1
Forward
€3.8B
/
Dec 2028
$511.5m
=
7.5
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
US
Quidel Corp
F:QL1
875.2m EUR 58 -0.8
JP
Hoya Corp
TSE:7741
9.8T JPY 34.1 39.1
US
Medline Inc
NASDAQ:MDLN
63.4B USD 0 0
CH
Alcon AG
SIX:ALC
30.5B CHF 29.1 39
DK
Coloplast A/S
CSE:COLO B
98.2B DKK 15.5 24.6
US
Align Technology Inc
NASDAQ:ALGN
13.7B USD 20 33.3
UK
ConvaTec Group PLC
LSE:CTEC
4.6B GBP 18.9 34.9
CA
Bausch + Lomb Corp
NYSE:BLCO
5.9B USD 56.2 -16.4
JP
Asahi Intecc Co Ltd
TSE:7747
895.2B JPY 32.6 50.6
KR
HLB Inc
KOSDAQ:028300
8.4T KRW -80.5 -38
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.4B USD 18.2 23.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Quidel Corp
F:QL1
Average EV/EBIT: 31.4
58
111%
0.5
JP
Hoya Corp
TSE:7741
34.1
N/A N/A
US
M
Medline Inc
NASDAQ:MDLN
Not Available
18%
N/A
CH
Alcon AG
SIX:ALC
29.1
26%
1.1
DK
Coloplast A/S
CSE:COLO B
15.5
7%
2.2
US
Align Technology Inc
NASDAQ:ALGN
20
21%
1
UK
ConvaTec Group PLC
LSE:CTEC
18.9
21%
0.9
CA
Bausch + Lomb Corp
NYSE:BLCO
56.2
72%
0.8
JP
A
Asahi Intecc Co Ltd
TSE:7747
32.6
N/A N/A
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -80.5 N/A N/A
US
Lantheus Holdings Inc
NASDAQ:LNTH
18.2
30%
0.6
P/E Multiple
Earnings Growth PEG
US
Quidel Corp
F:QL1
Average P/E: 35
Negative Multiple: -0.8
N/A N/A
JP
Hoya Corp
TSE:7741
39.1
15%
2.6
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
CH
Alcon AG
SIX:ALC
39
32%
1.2
DK
Coloplast A/S
CSE:COLO B
24.6
21%
1.2
US
Align Technology Inc
NASDAQ:ALGN
33.3
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
34.9
41%
0.9
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -16.4 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
50.6
40%
1.3
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -38 N/A N/A
US
Lantheus Holdings Inc
NASDAQ:LNTH
23.2
30%
0.8

Market Distribution

Higher than 95% of companies in the United States of America
Percentile
95th
Based on 8 638 companies
95th percentile
136.4
Low
0 — 13.6
Typical Range
13.6 — 27.8
High
27.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.6
Median 19.6
70th Percentile 27.8
Max 1 826 183.2

Quidel Corp
Glance View

Quidel Corporation, a player in the diagnostic healthcare industry, has steadily navigated the labyrinth of medical innovation, carving out a niche in rapid diagnostic testing. Born out of a mission to streamline the process of disease detection, Quidel has leveraged biotechnology to develop fast, reliable diagnostic solutions that address widespread health issues. This company’s arsenal includes tests for infectious diseases, reproductive health, and autoimmune disorders—each meticulously designed to expedite the diagnostic process while maintaining a stringent commitment to accuracy. By fostering partnerships with healthcare providers and aligning with technological advancements, Quidel has positioned itself as indispensable in the clinic setting, where swift decision-making can significantly impact patient care. At the heart of Quidel's business model is its focus on providing tangible value to both healthcare professionals and patients. The company generates revenue primarily through the sale of its diagnostic products, which are utilized in settings ranging from small clinics to large hospital networks. Quidel's innovative platforms, like the Sofia and Solana systems, are lauded for their efficiency and ease of use, attributes that resonate particularly well in medical environments under pressure to deliver fast and effective results. By effectively converting scientific expertise into practical and user-friendly applications, Quidel not only enhances patient outcomes but also fortifies its financial standing within the competitive landscape of medical diagnostics.

QL1 Intrinsic Value
190.06 EUR
Undervaluation 57%
Intrinsic Value
Price €81.28
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett